Supraorbital Transcutaneous Stimulator Prevents Migraines
(HealthDay News) – Treatment with a supraorbital transcutaneous stimulator seems safe and effective for preventing migraine headaches, according to a study published online Feb. 6 in Neurology.
Jean Schoenen, MD, PhD, from Liège University in Belgium, and colleagues randomized 67 patients with ≥2 migraine attacks/month to either verum or sham stimulation in a 1:1 ratio. Following a one-month run-in, the stimulator was applied daily for 20 minutes during three months.
The researchers found that, between run-in and the third month of treatment, there was a significant decrease in the mean number of migraine days in the verum group (6.94 vs. 4.88; P=0.023), but not in the sham group (6.54 vs. 6.22; P=0.608). In the verum group the 50% responder rate was significantly greater than in the sham group (38.1% vs. 12.1%; P=0.023). In the verum group, but not the sham group, monthly migraine attacks, monthly headache days, and monthly acute anti-migraine drug intake were all significantly reduced. Neither group experienced adverse events.
"This study provides Class III evidence that treatment with a supraorbital transcutaneous stimulator is effective and safe as a preventive therapy for migraine," the authors write.
Several authors disclosed financial ties to the medical device industry.